amazing, page-3

My 1/2 a cents worth:
I see two things currently "restraining" the MSB share price.

1) An unstable global fiscal outlook, so there's little "strategic value" reflected in many/any share prices. The great thing is MSB itself has a sound balance sheet and can make carefully considered steps forward, both on the business side and the clinical side.

2) The market is probably really looking for some sort of update and clearly that's not far off with the AGM.

The positive "gorilla in the room" for MSB is its quality people and a sound technology, which it appears will be applied, reasonably quickly, across a number of much needed medical treatment spaces, - subject now only to nothing major unforeseen occurring, which, fingers and toes crossed, appears increasingly unlikely (bold call, so I hope I am right).

When the mainstream media picks up on more of what's starting to get "very close" ie, 1-3yrs, the company will head for the stars and if its treatments deliver as everyone hopes, a lot of people will gladly applaud.